 Complement Inactivator Proteins
"Complement Inactivator Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.
| Descriptor ID |
D003169
|
| MeSH Number(s) |
D12.776.124.486.274.920
|
| Concept/Terms |
Complement Inactivator Proteins- Complement Inactivator Proteins
- Inactivator Proteins, Complement
- Proteins, Complement Inactivator
- Serum Complement Inactivators
- Complement Inactivators, Serum
- Inactivators, Serum Complement
- Complement Inactivating Proteins
- Inactivating Proteins, Complement
- Proteins, Complement Inactivating
|
Below are MeSH descriptors whose meaning is more general than "Complement Inactivator Proteins".
Below are MeSH descriptors whose meaning is more specific than "Complement Inactivator Proteins".
This graph shows the total number of publications written about "Complement Inactivator Proteins" by people in this website by year, and whether "Complement Inactivator Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 0 | 1 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 1 | 0 | 1 | | 2003 | 6 | 1 | 7 | | 2004 | 2 | 0 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement Inactivator Proteins" by people in Profiles.
-
Bomback AS, Appel GB, Gipson DS, Hladunewich MA, Lafayette R, Nester CM, Parikh SV, Smith RJH, Trachtman H, Heeger PS, Ram S, Rovin BH, Ali S, Arceneaux N, Ashoor I, Bailey-Wickins L, Barratt J, Beck L, Cattran DC, Cravedi P, Erkan E, Fervenza F, Frazer-Abel AA, Fremeaux-Bacchi V, Fuller L, Gbadegesin R, Hogan JJ, Kiryluk K, le Quintrec-Donnette M, Licht C, Mahan JD, Pickering MC, Quigg R, Rheault M, Ronco P, Sarwal MM, Sethna C, Spino C, Stegall M, Vivarelli M, Feldman DL, Thurman JM. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2022 04; 79(4):570-581.
-
Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, Baines AC, Merrill SA, Chaturvedi S, Blakemore K, Sperati CJ, Brodsky RA. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018 03 22; 3(6).
-
Renner B, Coleman K, Goldberg R, Amura C, Holland-Neidermyer A, Pierce K, Orth HN, Molina H, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Thurman JM. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol. 2010 Sep 01; 185(5):3086-94.
-
Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol. 2009 Nov 01; 183(9):5928-37.
-
Ricklin D, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, Wu YQ, Holers VM, Herbert AP, Barlow PN, Geisbrecht BV, Lambris JD. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol. 2009 Aug 15; 183(4):2565-74.
-
Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
-
Garantziotis S, Hollingsworth JW, Ghanayem RB, Timberlake S, Zhuo L, Kimata K, Schwartz DA. Inter-alpha-trypsin inhibitor attenuates complement activation and complement-induced lung injury. J Immunol. 2007 Sep 15; 179(6):4187-92.
-
Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol. 2006 Aug 01; 177(3):1904-12.
-
Lam TT, Hausen B, Hook L, Lau M, Higgins J, Christians U, Jacobsen W, Baluom M, Duthaler R, Katopodis A, Chavez G, Cozzi E, Harrison R, Schuurman HJ, Borie D, Morris RE. The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. Xenotransplantation. 2005 Jan; 12(1):20-9.
-
M?hlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int. 2004 Apr; 65(4):1214-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|